Abiraterone acetate : Prostate Cancer Treatment
ABIRASTERON 250 is a cutting-edge oral medication formulated with Abiraterone Acetate 250 mg, designed to effectively combat metastatic castration-resistant prostate cancer (mCRPC). As a potent androgen biosynthesis inhibitor, it works by blocking the production of androgens (male hormones), which play a critical role in the growth and spread of prostate cancer.
Approved for use in combination with prednisone or prednisolone, ABIRASTERON 250 has become a vital component of modern oncology protocols, helping to prolong survival and improve the quality of life for patients battling advanced stages of prostate cancer.
Key Features and Ingredients
Active Ingredient: Abiraterone Acetate 250 mg
Therapeutic Class: Androgen biosynthesis inhibitor
Mechanism of Action: Selectively inhibits CYP17 enzyme complex, reducing androgen production in the testes, adrenal glands, and prostate tumor tissues
Formulation: Oral tablet for systemic therapy
Use in Combination: Administered alongside a corticosteroid (e.g., prednisone) to counteract mineralocorticoid excess caused by CYP17 inhibition
Usage
ABIRASTERON 250 is prescribed for adult male patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) or metastatic high-risk castration-sensitive prostate cancer (mCSPC). The medication is typically used in conjunction with prednisone to enhance therapeutic outcomes and manage hormone imbalance.
Dosage and Administration:
Standard Dose: 1,000 mg per day (i.e., 4 tablets of ABIRASTERON 250)
Mode of Administration: Orally, on an empty stomach (at least one hour before or two hours after meals)
Adjunct Therapy: Prednisone 5 mg twice daily (as per physician’s direction)
Important Note: The medication must be used under strict medical supervision due to its hormonal effects and potential for drug interactions.
Benefits
Targets Hormonal Root of Cancer: By inhibiting the CYP17 enzyme, ABIRASTERON 250 drastically reduces the production of androgens, slowing tumor growth and disease progression.
Extends Overall Survival: Clinical trials have shown significant improvements in progression-free survival and overall survival in patients using Abiraterone Acetate.
Improves Quality of Life: Reduced pain, delayed skeletal-related events, and enhanced physical functioning are observed during treatment.
Non-Cytotoxic: Unlike traditional chemotherapy, ABIRASTERON 250 offers a non-cytotoxic alternative with a better safety and tolerability profile.
Well-Tolerated: When combined with corticosteroids, side effects are manageable, making long-term use more feasible for many patients.
Safety and Precautions
Regular Monitoring: Liver function, blood pressure, potassium levels, and cardiac health should be regularly monitored during treatment.
Contraindications: Not to be used in women, especially those who are or may become pregnant.
Drug Interactions: Should not be co-administered with strong CYP3A4 inducers or substrates without caution.
Conclusion
ABIRASTERON 250, with Abiraterone Acetate 250 mg as its active component, represents a significant advancement in the management of advanced prostate cancer. By targeting the hormonal drivers of the disease, it not only slows down tumor progression but also offers patients a chance at a longer, more comfortable life. With its proven efficacy, patient-friendly formulation, and robust clinical backing, ABIRASTERON 250 continues to be a cornerstone therapy in the fight against metastatic prostate cancer.
Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options. The company offers a wide range of healthcare products, catering to various medical needs, from rare disease treatments to essential healthcare products. Sterispharma's product range includes solutions for Cardiology, Asthma, Respiratory Issues, Nasal Conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/Antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental Care, and Dermatology. Medicines can be conveniently ordered via Our websites—Sterisonline, Sterisindia, and Sterispharma.
For further information
Email: info@sterispharma.com / contact@sterispharma.com
Call/WhatsApp: 8209542042 , 8824175417
